To determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias.~To determine the 2 and 3 year rate of locoregional disease control.~To evaluate the safety and toxicity of the combination of cetuximab and concomitant-boost accelerated radiotherapy followed by 12 weeks of complementary treatment with cetuximab. Both acute and chronic toxicity will be assessed.~To determine specific disease-free survival, event-free survival, disease-specific survival and overall survival~To determine acute and late toxicity~To determine EGFR, p53, Ki67, and evaluate its value as a prognostic factor.
The purpose of this study is to determine the 1-year rate of locoregional disease control in the experimental arm, using a control arm to avoid selection bias.